Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

Johnson & Johnson And Global Partners Announce Results From Phase 2b Imbokodo HIV Vaccine Clinical Trial In Young Women In Sub-Saharan Africa; Data Showed Regimen ‘did not provide sufficient protection against HIV infection,’ Study Will Not Continue

ohnson & Johnson (NYSE:JNJ), together with a consortium of global partners, today announced results from the primary analysis of a Phase 2b HIV vaccine clinical trial known as the Imbokodo study (also known

JNJ